H

Hualan Biological Bacterin Inc
SZSE:301207

Watchlist Manager
Hualan Biological Bacterin Inc
SZSE:301207
Watchlist
Price: 19.12 CNY -5.3% Market Closed
Market Cap: 11.5B CNY
Have any thoughts about
Hualan Biological Bacterin Inc?
Write Note

Hualan Biological Bacterin Inc
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hualan Biological Bacterin Inc
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
H
Hualan Biological Bacterin Inc
SZSE:301207
Total Current Assets
ÂĄ5.2B
CAGR 3-Years
28%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Current Assets
ÂĄ29.8B
CAGR 3-Years
-3%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Current Assets
ÂĄ10.3B
CAGR 3-Years
73%
CAGR 5-Years
64%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Total Current Assets
ÂĄ8.2B
CAGR 3-Years
11%
CAGR 5-Years
14%
CAGR 10-Years
18%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Current Assets
ÂĄ46.8B
CAGR 3-Years
36%
CAGR 5-Years
48%
CAGR 10-Years
40%
Imeik Technology Development Co Ltd
SZSE:300896
Total Current Assets
ÂĄ4.3B
CAGR 3-Years
-1%
CAGR 5-Years
70%
CAGR 10-Years
N/A
No Stocks Found

Hualan Biological Bacterin Inc
Glance View

Market Cap
11.5B CNY
Industry
Biotechnology

Hualan Biological Bacterin Inc is a CN-based company operating in Biotechnology industry. The company is headquartered in Xinxiang, Henan and currently employs 917 full-time employees. The company went IPO on 2022-02-18. Hualan Biological Bacterin Inc is a China-based company specializing in the research, development, production and sales of human vaccines. The firm's listed products mainly include influenza virus split vaccine, quadrivalent influenza virus split vaccine, influenza A H1N1 split vaccine, recombinant hepatitis B vaccine and others. The firm's products that have been approved for clinical trials or have passed clinical registration and are pending for marketing mainly include human rabies vaccines, adsorbed tetanus vaccines, H7N9 influenza whole virus inactivated vaccines and others. The firm's products in the preclinical research stage include inactivated new coronavirus vaccine, freeze-dried nasal spray recombinant new coronavirus live attenuated vaccine and others.

Intrinsic Value
30.08 CNY
Undervaluation 36%
Intrinsic Value
Price
H

See Also

What is Hualan Biological Bacterin Inc's Total Current Assets?
Total Current Assets
5.2B CNY

Based on the financial report for Dec 31, 2023, Hualan Biological Bacterin Inc's Total Current Assets amounts to 5.2B CNY.

What is Hualan Biological Bacterin Inc's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
40%

Over the last year, the Total Current Assets growth was 25%. The average annual Total Current Assets growth rates for Hualan Biological Bacterin Inc have been 28% over the past three years , 40% over the past five years .

Back to Top